Engels FK - Search Results

1

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.

de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, de Raaf PJ, de Bruijn P, Engels FK, Eskens FA, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH. de Graan AJ, et al. Among authors: engels fk. Clin Cancer Res. 2013 Jun 15;19(12):3316-24. doi: 10.1158/1078-0432.CCR-12-3786. Epub 2013 May 2. Clin Cancer Res. 2013. PMID: 23640974 Free PMC article.

2

Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.

Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A. Engels FK, et al. Clin Pharmacol Ther. 2004 May;75(5):448-54. doi: 10.1016/j.clpt.2004.01.001. Clin Pharmacol Ther. 2004. PMID: 15116057 Clinical Trial.

3

Medicinal cannabis in oncology practice: still a bridge too far?

de Jong FA, Engels FK, Mathijssen RH, van Zuylen L, Verweij J, Peters RP, Sparreboom A. de Jong FA, et al. Among authors: engels fk. J Clin Oncol. 2005 May 1;23(13):2886-91. doi: 10.1200/JCO.2005.04.150. J Clin Oncol. 2005. PMID: 15860846 No abstract available.

4

Docetaxel administration schedule: from fever to tears? A review of randomised studies.

Engels FK, Verweij J. Engels FK, et al. Eur J Cancer. 2005 May;41(8):1117-26. doi: 10.1016/j.ejca.2005.02.016. Eur J Cancer. 2005. PMID: 15911234 Review.

5

Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.

Engels FK, Sparreboom A, Mathot RA, Verweij J. Engels FK, et al. Br J Cancer. 2005 Jul 25;93(2):173-7. doi: 10.1038/sj.bjc.6602698. Br J Cancer. 2005. PMID: 16012521 Free PMC article. Review.

6

Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method.

Engels FK, Buijs D, Loos WJ, Verweij J, Bakker WH, Krenning EP. Engels FK, et al. Anticancer Drugs. 2006 Jan;17(1):63-7. doi: 10.1097/01.cad.0000185183.57357.c2. Anticancer Drugs. 2006. PMID: 16317291

7

Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.

Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J. Engels FK, et al. Cancer Biol Ther. 2006 Jul;5(7):833-9. doi: 10.4161/cbt.5.7.2839. Epub 2006 Jul 22. Cancer Biol Ther. 2006. PMID: 16775418 Free article. Clinical Trial.

8

Alternative drug formulations of docetaxel: a review.

Engels FK, Mathot RA, Verweij J. Engels FK, et al. Anticancer Drugs. 2007 Feb;18(2):95-103. doi: 10.1097/CAD.0b013e3280113338. Anticancer Drugs. 2007. PMID: 17159596 Review.

9

Influence of ketoconazole on the fecal and urinary disposition of docetaxel.

Engels FK, Loos WJ, Mathot RA, van Schaik RH, Verweij J. Engels FK, et al. Cancer Chemother Pharmacol. 2007 Sep;60(4):569-79. doi: 10.1007/s00280-006-0412-5. Epub 2007 Jan 26. Cancer Chemother Pharmacol. 2007. PMID: 17256132 Free article.

10

Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.

Engels FK, de Jong FA, Sparreboom A, Mathot RA, Loos WJ, Kitzen JJ, de Bruijn P, Verweij J, Mathijssen RH. Engels FK, et al. Oncologist. 2007 Mar;12(3):291-300. doi: 10.1634/theoncologist.12-3-291. Oncologist. 2007. PMID: 17405893 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters